Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays.
Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays.
复制标题
DOI：
10.1158/1078-0432.ccr-21-2181
复制
发表时间：
2021-10-15
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
循环肿瘤 DNA (ctDNA) 已成为结直肠癌 (CRC) 的非侵入性诊断和预后工具。在这里，我们讨论评估纯血浆 ctDNA 检测检测微小残留病 (MRD) 能力的研究，以及将甲基化整合到 ctDNA 检测中的潜在益处。
Circulating tumor DNA (ctDNA) has emerged as a non-invasive diagnostic and prognostic tool for colorectal cancer (CRC). Here, we discuss studies that evaluate the ability of plasma-only ctDNA assays to detect minimal residual disease (MRD) and the potential benefit of integration of methylation into ctDNA assays.